Joint-preserving regenerative therapy for patients with early-stage osteonecrosis of the femoral head

Kuroda, Yutaka; Matsuda, Shuichi; Akiyama, Haruhiko

doi:10.1186/s41232-016-0002-9

Inflammation and Regeneration

Table 1 Joint-preserving regenerative therapy-based core decompression

From: Joint-preserving regenerative therapy for patients with early-stage osteonecrosis of the femoral head

First author year/design	Technique	Number of hips (precollapse)	Background factors for ONFH (%)	Mean age (years)	Mean follow-up (years)	Hip survivorship (%)
Tsao [34] 2005/P	CD	94	S 41, A 24, I 30, others 5	43	4.0	80.4
Tsao [34] 2005/P	TR	94	S 41, A 24, I 30, others 5	43	4.0	80.4
Veillette [35] 2006/R	CD	50	S 45, A 3, I 26, T 10, others 16	35	4.0	66.7
Veillette [35] 2006/R	TR	50	S 45, A 3, I 26, T 10, others 16	35	4.0	66.7
Floerkemeier [36] 2011/P	CD	23	NR	40	1.4	43.5
Floerkemeier [36] 2011/P	TR	23	NR	40	1.4	43.5
Yu [37] 2015/P	CD	6	S 5, A 68, I 21, T 5	48	1.4	50.0
Yu [37] 2015/P	CaSO₄/CaPO₄	6	S 5, A 68, I 21, T 5	48	1.4	50.0
Hernigou [16] 2009/P	CD	534	S 19, SCD 31, I 28	39	13.0	82.4
Hernigou [16] 2009/P	BMMNC	534	S 19, SCD 31, I 28	39	13.0	82.4
Gangji [13] 2011/RCT	CD	11	S 82, A 9, I 9	45.7	5.0	27.3
Gangji [13] 2011/RCT	ᅟ	11	S 82, A 9, I 9	45.7	5.0	27.3
Gangji [13] 2011/RCT	CD	13	S 85, A 8, I 8	42.2	5.0	76.9
Gangji [13] 2011/RCT	BMMNC	13	S 85, A 8, I 8	42.2	5.0	76.9
Civinini [41] 2012/P	CD, BMC,	30	S 49, A 35, I 16	43.9	1.7	83.3
Civinini [41] 2012/P	CaSO₄/CaPO₄	30	S 49, A 35, I 16	43.9	1.7	83.3
Yamasaki [42] 2010/R	CD	9	S 22, A 44, I 33	49	2.4	0
Yamasaki [42] 2010/R	HA	9	S 22, A 44, I 33	49	2.4	0
Yamasaki [42] 2010/R	CD, BMMNC,	27	S 73, A 20, I 7	41	2.4	56.7
Yamasaki [42] 2010/R	HA	27	S 73, A 20, I 7	41	2.4	56.7
Lieberman [17] 2004/P	CD, FBG	16	S 76, A 18, S&A 6	47	4.4	87.5
Lieberman [17] 2004/P	rhBMP 50 mg	16	S 76, A 18, S&A 6	47	4.4	87.5
Papanagiotou [43] 2014/P	CD, FBG	5	S 40, A 20, I 40	32	4.0	80.0
Papanagiotou [43] 2014/P	rhBMP 3.5 g	5	S 40, A 20, I 40	32	4.0	80.0
Kuroda [23] 2015/P	CD	10	S 80, A 20	39.8	1.0	90.0
Kuroda [23] 2015/P	rhFGF-2 800 μg	10	S 80, A 20	39.8	1.0	90.0

P prospective study, R retrospective study, RCT randomized clinical trial, CD core decompression, TR tantalum rod, BMMNC bone marrow mononuclear cell, BMC bone marrow cell, HA hydroxyapatite, FBG fibular bone graft, rhBMP recombinant human bone morphogenetic protein, ONFH osteonecrosis of the femoral head, S steroid use, A alcohol intake, I idiopathic, T trauma, NR not reported, SCD sickle cell disease

Back to article page

ISSN: 1880-8190

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com